What do TSECs provide in the menopausal hormone therapy?

Area of Science:

• Endocrinology
• Women's Health
• Pharmacology

Background:

• Postmenopausal estrogen deficiency causes significant symptoms.
• Traditional hormone therapy often requires progestins, which can have side effects.
• Tissue-selective estrogen complex (TSEC) presents a progestogen-free alternative.

Purpose of the Study:

• To analyze the efficacy and safety of TSEC (conjugated estrogens [CE]/bazedoxifene acetate [BZA]) in postmenopausal women.
• To evaluate TSEC as a progestogen-free option for managing estrogen deficiency symptoms.
• To compare TSEC's benefits against placebo and traditional menopausal hormone therapy (MHT).

Main Methods:

• Review of randomized clinical trials comparing CE/BZA TSEC with placebo or MHT.
• Assessment of symptom alleviation, quality of life improvements, and vaginal atrophy.
• Evaluation of bleeding patterns, amenorrhea rates, and mammary repercussions.

Main Results:

• TSEC (CE 0.45 mg/BZA 20 mg) effectively alleviates vasomotor symptoms.
• Improvements observed in quality of life and vaginal atrophy.
• Favorable bleeding patterns, higher amenorrhea rates, and reduced mammary repercussions compared to progestin-containing MHT.

Conclusions:

• TSEC (CE/BZA) is an effective and safe progestogen-free option for postmenopausal women.
• Offers benefits in symptom management and tolerability over traditional MHT.
• Represents a significant advancement in managing estrogen deficiency symptoms without progestins.